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Abstract 
Achilles tendon injuries are common, and present a challenge in the acute and chronic setting. There is 
significant morbidity associated with the injury and the numerous management strategies, as well as financial 
implications to the patient and the health service. To date, repair tissue from all methods of management fail to 
achieve the same functional and biomechanical properties as the native tendon. The use of tissue engineering 
technology may reduce morbidity, improve the biomechanical properties of repair tissue and reduce the 
financial burden. The goal is to produce completely integrated tendon repair tissue that has the functional and 
mechanical properties of the native tendon. This review evaluates the role of stem cells in tissue engineering for 
tendon reconstruction and the various sources for harvesting stem cells. They can be obtained from the embryo, 
foetus or adult, and require the correct conditions for proliferation and differentiation. There remain many 
ethical concerns with the use of embryo or foetus harvested stem cells, thus the focus remains on adult sources, 
haematopoietic and non-haematopoietic. The improving knowledge of the role of growth factors is addressed, as 
is their effect on animal models for tendon repair. Growth factors include bone morphogenic proteins, 
transforming growth factor β, insulin-like growth factor and platelet derived growth factor. The role of scaffolds 
in human and animal models is reviewed, both naturally derived and synthetic scaffolds. Whilst numerous 
animal studies have reported encouraging results, further work is required. 
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Introduction 
The Achilles tendon, formed by the union of the medial and lateral heads of the gastrocnemius muscle with the 
soleus muscle, is the strongest tendon in the body and inserts on the calcaneum [1]. The main arterial supply 
arises from the posterior tibial artery, which supplies the proximal and distal thirds of the tendon. The middle 
third, supplied by the peroneal artery, is relatively hypo-vascular and is a common site for tendon degeneration 
and rupture [2]. Achilles tendon rupture is reported to have an incidence of 11.3/100,000 per year [3].  
 
Tendons are composed of a cellular component (fibroblast cells) and extracellular matrix. Water forms the 
majority of the extracellular matrix (70%); with collagen, ground substance and elastin composing the rest [4]. 
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Within the human body, collagen types I, II and III are most frequently found, with type I dominating in tendons 
due to its high tensile strength. Type III collagen tends to be seen in greater proportion in healing tendon tissue 
[5]. A tendon attaches muscle to bone, transferring muscular force to the attached bone that can produce 
movement. Collagen, a triple-stranded helical molecule, is organised into parallel bundles of fibrils orientated to 
the direction of force. These fibrils group together to form fascicles that are enveloped by connective tissue 
layers. The vascularity of tendons is dependent on whether they are enclosed in sheath; with those within a 
sheath having avascular regions compared to those without a sheath. The vascular supply is from the musculo-
tendinous junction, osteo-tendinous junction and vesicles within surrounding soft tissues. Within the endotenon, 
longitudinal arranged vessels are seen, which anastomose with periosteal vessels at the bone insertion site. In 
those tendons enclosed in a sheath, vessels enter along the tendon via vinculae in a segmental distribution, with 
adjacent areas supplied by diffusion. Those without a sheath have blood vessels passing into the tendon at any 
point through the paratenon [6]. 
 
Injuries to the Achilles tendon heal through three stages: haemostasis and inflammation, matrix and cellular 
proliferation, and maturation. During the first stage of repair the edges of the injury site are stabilised by 
formation of a fibrin clot following inflammatory cell and platelet aggregation. Fibroblasts then infiltrate and 
proliferate at the site of injury, producing extracellular matrix. Damaged tendons heal by scar formation that has 
inferior mechanical properties compared to the native tendon. Finally, matrix metalloproteinase degrade the 
collagen matrix, and collagen type 1 replaces collagen type III. These collagen fibres are organised in alignment 
of the direction of force [4]. 
 
The management of Achilles tendon injuries is dependent on the severity and location of the rupture.  Non-
operative measures may include splintage, exercises and pain management. Operative treatment options include 
debridement, repair and reconstruction with graft. The current treatment modalities have limited clinical 
evidence and have a significant complication and failure rate [3]. The goal is to be able to produce completely 
integrated tendon repair tissue that has the functional and mechanical properties of the native tendon.  Given the 
lack of clinical evidence of current treatment options as well as associated morbidity and financial implications, 
research into the application of stem cells for cell-based strategies have gained momentum in recent years.  
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Stem cells 
Stem cells can be obtained from the embryo, foetus or adult, and can reproduce for long periods under correct 
conditions. The stem cell develops by proliferation and differentiation, and each cell division being either 
symmetrical or asymmetrical. Symmetrical division means either two stem cells are produced or two terminally 
differentiated cells have resulted. With asymmetrical division the result is one stem cell and one terminally 
differentiated cell [4]. With increasing cell divisions the differentiation potential declines [7]. Embryonic stem 
cells, originating from the inner cell mass of the blastocyst, are harvested from eggs that are fertilized in vitro. 
They have pluripotent potential and can differentiate into any lineage. As the embryo develops the cells being 
produced demonstrate reduced phenotypic potential, limited degrees of differentiation and self-renewal 
potential, with greater rate of cell proliferation [7]. There are many ethical concerns associated with the use of 
stem cells from the embryo or foetus, and thus preclude their clinical use. Adult stem cells, haematopoietic or 
non-haematopoietic, maintain their multilineage potential [8]. 
 
Mesenchymal stem cells (MSCs) are multipotent, non-haematopoietic adult stem cells that are derived from the 
mesodermal germinal layer [9,10]. MSCs have multilineage potential with the ability to differentiate along 
chondrogenesis, adipogenesis and osteogenesis lineages [11]. MScs were first reported in bone marrow by 
Friedenstein et al. [12], and demonstrated their intrinsic ability to adhere to tissue culture plastic that enabled 
isolation. Further analysis found these cells to be a heterogeneous population of stem cells that were at different 
stages of differentiation potential [13,14]. The cell surface antigens on these non-haematopoietic stem cells 
allow them to be distinguished from haematopoietic stem cells [13,14]. They have higher levels of proliferation 
and collagen synthesis and survive longer compared to terminally differentiated cells. MSCs also have a low 
risk of immune reaction in the host whether autologous or allogenic, as they express no class II major 
histocompatibility complex (MHC). 
 
A number of studies have reported encouraging outcomes in tissue regeneration using MSCs with scaffolds in 
animal models. Achilles tendon ruptures in rabbits treated with MSCs demonstrated significantly greater 
structural and material properties compared with controls [15]. With the injection of chondrocytes or MSCs 
there was improved healing at the Achilles tendon-bone interface in rat models, with the new enthesis organised 
like native enthesis tissue in the MSCs group [16]. Whilst Juncosa-Melvin et al. [17] reported greater maximum 
force and stress in MSCs seeded autogenous tissue-engineered constructs compared with constructs without 
 5 
MSCs in repair of rabbit patella tendons. Awad et al. [18] also reported significantly improved repair in those 
that had MSCs injected into rabbit patella tendon defects. Ligament integration in bone tunnels and 
biomechanical strength were improved with MSCs coated or incorporated in grafts [19,20]. 
 
The mechanism of action of stem cells is still not fully understood. Whilst it is assumed that the stem cells 
undergo incorporation and proliferation in the host, alternate mechanisms of action exist. Some studies have 
shown that only a small proportion of the cells persist at the transplant site, and that the action of the MSCs may 
be due to the local release of paracrine factors with angiogenic, trophic and anti-inflammatory properties.  
 
Sources of MSCs 
Bone marrow 
Bone marrow contains both MSCs and haematopoietic stem cells. Although bone marrow derived MSCs 
(BMSCs) form <0.01% of the nucleated cells obtained in bone marrow aspirates, they have been shown to have 
the greatest potential for differentiation into multiple cell lines. However, the technique of bone marrow 
aspiration itself is painful and may cause donor site morbidity [10]. 
 
Lee et al. [21] characterized the differentiation of BMSCs into tenocyte-like cells in the presence of bone 
morphogenetic protein-12 (BMP-12). They found that exposure to BMP-12 markedly increased the expression 
of scleraxis (Scx) and tenomodulin (Tnmd), which are markers of tenocyte lineage. Subsequent colonies 
demonstrated a persistent elevation in these markers. In addition, they found that BMSCs seeded in collagen 
scaffolds and similarly treated also expressed high levels of Scx and Tnmd, as well as type I collagen and 
tenascin-c.  When these scaffolds were implanted into surgically created tendon defects in vivo, they generated 
tendon-like tissue with an increase in cell numbers, which were aligned along the tensile axis. Increased matrix 
deposition and elevated expression of tendon markers was also demonstrated.  
 
Huang et al. [22] studied the effect of BMSCs in a rat Achilles tendon injury model. The cut Achilles tendons in 
the rats were injected with hypoxic BMSC, normoxic BMSC, or not treated. They demonstrated that BMSCs 
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improved the ultimate load to failure, with higher loads to failure in the group treated with hypoxic BMSCs. The 
BMSC groups had stronger immunostaining for type I and type III collagen, and bromodeoxyuridine (BrdU) 
labelling of the stem cells showed retention of the injected cells at the site of the tendon rupture. 
 
The effects of MSCs on tendon healing in a rat tendon model has been reported [23], where the groups were 
randomized into suture repair only, suture repair with MSC injection, and repair with suture loaded with stem 
cells. There was significantly higher ultimate failure strength in both the MSC groups, with better maintenance 
of strength and histology in the suture loaded with stem cells group. 
 
Adipose Tissue 
Adipose tissue contains a population of stem cells that are similar to BMSCs. The advantages of adipose derived 
stem cells include the ease of harvesting, ready availability and low donor site morbidity. They have been shown 
to have multilineage potential by Zuk et al. [24] 
 
James et al. [25] studied the effect of growth differentiation factor 5 (GDF-5) on rat adipose tissue-derived 
mesenchymal stem cells (AT-MSCs) that were cultured on a poly(DL-lactide-co-glycolide) (PLGA) fibre 
scaffold, which mimics the collagen structure of native tendon, as well as on a PLGA 2D film scaffold. They 
found increased expression of tendon markers including Scx, as well as genes for Type I collagen. In addition, 
the AT-MSCs cultured on the fibre scaffold showed increased expression of these markers when compared to 
those cultured on 2D film.  
 
A study looking at the effect of AT-MSCs in a rabbit Achilles tendon healing model comparing platelet-rich 
plasma (PRP) gel and autologous AT-MSCs mixed with PRP was reported by Uysal et al. [26] At 4 weeks the 
AT-MSCs mixed with PRP group had a higher tensile strength compared to the PRP gel group. There was also 
an increase in collagen type I, fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF), 
and a decrease in transforming growth factor beta (TGF-β) in the AT-MSC treated group. There was increased 
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neovascularization in tendons treated with AT-MSCs on doppler ultrasonography as well as histologic analysis 
in an equine superficial digital flexor tendon (SDFT) model study by Conze et al. [27] 
 
Synovium 
The synovium is a readily accessible tissue for harvesting, with minimal donor site morbidity. Ju et al. [28] 
investigated the use of synovial MSCs in the healing of an Achilles tendon graft into a bone tunnel in a rat 
model. They found the labelled MSCs to be localized at the bone-tendon interface. There was accelerated 
tendon to bone integration in the MSC group, with an increase in the proportion of oblique collagen fibres 
(Sharpey’s fibres) in the MSC group. Synovial derived MSCs have been reported to have superior chondrogenic 
potential than those from other sources [29]. These effects may have relevance in the treatment of insertional 
Achilles tendinopathy. 
 
Peripheral Blood 
MSCs are found in the circulating blood. Raghunath et al. [30] cultured peripheral blood mononuclear cells and 
found that there is a distinct cell group which could be cultured that were positive for cell surface markers 
CD105 and CD14 and expressed collagen I and II precursors. These cells did tend to demonstrate chondrogenic 
potential, however a variety of connective tissue could be produced in the correct environment. Collagen type II 
tissue has been produced from isolated adult pluripotent cells from peripheral blood monocytes [31]. Giovannini 
et al. [32] demonstrated that equine fibroblast–like cells derived from the peripheral blood can be directed 
towards adipogenic, chondrogenic and osteogenic differentiation.  
 
It has been suggested that peripheral blood MSCs may actually be derived from the vascular tissue, and tends to 
yield lower levels of MSCs [33]. Umbilical cord derived MSCs has also been suggested as a good source, with 
shorter doubling times and longer time to senescence if compared to BMSCs. The role of peripheral blood 
derived MSCs in tendon repair and regeneration is yet to be determined. 
 
Muscle/Periosteum/Tendon 
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Periosteum contains multipotent, mesodermal cells with the potential to form a variety of connective tissues. 
Tawonsawatruk et al. [34] studied the growth kinetics of rat mesenchymal stem cells derived from bone 
marrow, periosteum and adipose tissue and found that periosteum derived stem cells were comparable to 
BMSCs with similar growth curves and population doubling times. Kisiel et al. [35] compared the proliferative 
capacities of bone marrow-, adipose tissue-, muscle-, and periosteum-derived MSCs from canine muscle and 
periosteum and found that all had similar proliferative capacity, however periosteum provided a significantly 
higher MSC yield per gram of tissue. The use of periosteum at the graft-bone interface has been suggested to 
augment tendon repair. A study by Chen et al. [36] found that a periosteum cover over transplanted tendons in 
rabbit tibial tunnels formed a fibrous layer interface. This interface subsequently became a fibre-bone 
intermixture and anchorage, with progressive incorporation and organisation. 
 
The role of muscle derived MSCs have been investigated in animal models by Wada et al. [37]. It was reported 
that they underwent terminal osteogenic differentiation in vitro, with bone formation. Tendon derived stem cells 
(TDSC) have also been evaluated, with Cheng et al. [38] suggesting that BMSCs had better osteogenic potential 
than anterior cruciate ligament (ACL) derived MSCs. Although, these ACL derived MSCs demonstrated faster 
proliferation and with basic fibroblast growth factor (bFGF) could maintain an undifferentiated state. Thus, 
better outcomes were reported from ACL derived MSCs compared to BMSCs. Zhang et al. [39] studied TDSCs 
and tenocytes isolated from the patellar tendon and Achilles tendon of rabbits, and found that TDSCs were able 
to differentiate into adipocytes, chondrocytes, and osteocytes in vitro, and form tendon-like tissues in vivo. In 
addition, TDSCs from patellar tendons formed more numerous and larger colonies and proliferated more rapidly 
than TDSCs from Achilles tendons. Tan et al. [40] compared rat TDSCs and BMSCs in vitro. They found that 
TDSCs exhibited higher clonogenicity, proliferated faster, and expressed higher TnmD, Scx, collagen 1 α 1 
(Col1A1) than BMSC.  
 
MSCs derived from bone marrow, synovium, periosteum, skeletal muscle and adipose tissue were compared by 
Sakaguchi et al. [29] It was found that cells derived from bone marrow, synovium and periosteum retained their 
expansion potential at later passages. There was greater colony numbers derived from synovium, periosteum, 
adipose tissue and muscle compared to bone marrow. BMSCs and periosteum derived MSCs were superior in 
osteogenesis, whilst synovium and adipose derived MSCs were superior in adipogenesis. 
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Growth Factors 
Transforming Growth Factor β (TGF-β) family 
These are a complex group of growth factors that are critical for embryonic development, which include the 
bone morphogenic proteins (BMP) and TGF-β which play a critical role in tendon and bone development. 
 
The effect of Transforming Growth Factor β1 (TGF-β1) on the healing of rat Achilles tendon repair has been 
reported by Kashiwagi et al. [41] There was a dose dependent increase in the expression of procollagen type I 
and II messenger ribonucleic acids (mRNAs), and a higher failure to load and stiffness of the healing tendon in 
the TGF-β1 treated group. A study looking at the effect TGF-β1 on surgically transected rat Achilles tendons in 
rats using adenovirus-modified muscle grafts found accelerated healing of the tendon, with earlier return to 
normal histological appearance, accelerated restoration of mechanical strength, decreased deposition of type III 
collagen bundles and an increase in type I collagen bundles [42]. They also noted accelerated remodelling of 
tendon thickness. 
 
A similar model was used to study the effect of BMP-12 on the healing of rat Achilles tendon, using a muscle 
flap modified by adenovirus carrying BMP-12 [42].  A higher load to failure was noted, as well as higher tendon 
stiffness and a more organized and homogeneous pattern of collagen fibres in the BMP-12 treated groups. There 
was also acceleration of tendon healing, with an earlier shift from fibroblasts to fibrocytes within the healing 
tendon. Pelled et al. [43] compared the effect of genetically modified MSCs over expressing BMP-2 and Smad8 
with non–modified MSCs and controls in a mouse Achilles tendon repair model. They reported that the 
genetically modified MSC group showed a better material distribution and functional recovery than control 
groups, and also demonstrated the highest effective stiffness and elastic modulus. 
 
The role of TGF-β and BMP-2 in injuries at the bone-tendon junction in a rabbit Achilles tendon model has 
been investigated by Kim et al.[44] who noted that the addition of TGF-β to fibrin glue did not improve the 
biomechanical properties of repair tissue. However, BMP-2 in combination with fibrin glue accelerated the 
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healing and also improved the histological and biomechanical properties of the repair. The effects of BMP-14 
(Growth Differentiation Factor 5 (GDF5)) in a rat tendon suture repair model, with the suture acting as a carrier, 
were studied by Dines et al.[45]. Histologic analysis demonstrated improved healing in the GDF5 treated 
tendons by three weeks, as well as significantly higher ultimate tensile load and stiffness compared with 
controls, however there was no difference at six weeks. 
 
Insulin-like Growth Factor (IGF) Family 
IGF-I is a growth factor closely related to insulin that performs many functions, including mediation of growth 
hormone activity, stimulating proliferation of multiple cell types including tenocytes, and has been identified in 
tendons [46]. IGF-I has been shown to enhance collagen formation in the human patellar tendon [47].  
 
Platelet Derived Growth Factor (PDGF) 
PDGF is a glycoprotein that is required by various cell groups including fibroblasts for optimal growth and cell 
proliferation. PDGF-BB has been shown to induce collagen type I mRNA in equine tendon cultures [48]. Intra-
tendon delivery of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) has been shown to 
cause a dose-dependent, transient increase in cell proliferation and sustained improvement in biomechanical 
properties of Achilles tendon repair in a rat collagenase-induced tendinopathy model [49]. rhPDGF-BB has also 
been shown to improve remodelling in a rat Achilles tendon transection model with a vicryl suture carrier, by 
significantly decreasing the resulting cross-sectional area, thus improving the material properties of the repaired 
tendon. In view of these findings, PDGF shows a promising role in treating tendinopathy. 
 
Scaffolds 
An appropriate scaffold in tissue engineering is key component to promote integration, growth and 
biomechanical support [50]. Collagen, silk and synthetic polymers are some of the biomaterials that have been 
investigated to date. An optimal scaffold should have the mechanical strength to allow immediate load bearing 
and integrate with host tissue, whilst balancing this with appropriate rate of biodegradation. 
 
 11 
Synthetic biodegradable three-dimensional (3D) polymer scaffolds such as polylactic acid (PLA), polyglycolic 
acid (PGA) and PLGA have been investigated. These polymers degrade by hydrolysis and can be custom 
fabricated to match local environmental and mechanical properties. Lu et al. [51] produced a braided 3D 
scaffold of poly(L-lactic acid) (PLLA) to replicate the structure of native ligament collagen fibrils in a rabbit 
ACL model. The study reported a good amount of matrix formation when the scaffold was immersed in human 
recombinant fibronectin. Further work is being performed to determine the optimum braiding angle of the 
scaffold to accurately represent and produce native tissue [52]. Synthetic polymers may also take the form of 
gels or sponges. Sponge scaffolds have been fabricated from PLGA immersed in bovine collagen type 1 
solution, creating a porous structure with the mechanical and cellular properties desired for tendon 
reconstruction [53]. In this study canine ACL fibroblasts were cultured on the scaffold in vitro, prior to rolling 
and implantation into mice, resulting in uniform matrix formation with cell viability. 
 
The use of synthetic polymers allows the scaffolds to be fabricated into a structure similar in size and orientation 
as native collagen fibrils, with nanometre scale accuracy. The nanofiber scaffolds are reported to culture more 
collagen mass from seeded human ligament cells compared to that produced in randomly orientated scaffolds 
[54]. Composite scaffolds involving nanofiber (hydrophilic properties and high surface area) and microfiber 
(providing mechanical strength and degradation resistance) scaffolds have been investigated with seeded 
porcine BMSCs [55]. The results have been encouraging with high matrix production. Whilst current literature 
supports the use of aligned nanofiber scaffolds, further work is required to determine the ideal material, fibre 
diameter, braiding angle and spacing of fibres. One of the disadvantages of current synthetic scaffolds is that 
they may release by-products during degradation, which can enter the bloodstream and lead to toxicity.  
Scaffolds derived from natural tissue have this advantage over synthetic polymers and various studies have 
investigated their role. 
 
The use of collagen type 1 as a scaffold for tendon and ligament reconstruction has been considered, however 
current technology is unable to organise the fibres into a biocompatible structure. Attempts to use this scaffold 
have resulted in a biomechanically weak structure [56]. Silk fibroin, demonstrates good tensile strength and 
toughness [57], has had encouraging results as a scaffold. This material has surface amino acids for cell 
adhesion (a property that synthetic scaffolds lack), it also degrades slowly and can be manufactured as a gel, 
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braided fibre or nanofiber [58,59]. Studies investigating braided silk fibres in scaffolds seeded with human 
BMSCs reported good cell numbers and matrix production with in vitro culture [60].  Composite naturally 
derived scaffolds are being investigated, with a combination of braided structures and sponge scaffolds of 
particular interest with good early results. 
 
Decellularized tendon tissue is another naturally derived scaffold that maintains its native structure and 
composition, as well as the mechanical properties of the tendon extracellular matrix [61]. Farnebo et al.[62] 
reported that the use of decellularized Achilles tendon graft in a rat model resulted in improved mechanical 
properties and reduced immune response compared to untreated grafts. The role of acellular human tissue, in 
form of human dermal allograft, has also been studied in Achilles tendon healing. Cadaveric studies 
demonstrated improved mechanical strength [63] and no complications in small retrospective studies in patients 
[64,65].  
 
Xenograft scaffolds have shown good initial results in tendon repair in vitro. Porcine small intestinal submucosa 
has been utilised as a scaffold for tissue engineering, demonstrating an ability to remodel into tendon tissue [66]. 
This is likely due to the retention of active growth factors that are involved in migration of cells to the scaffold 
[61]. This scaffold showed rapid degradation (60% by four months) and recruitment of marrow-derived cells 
that are involved in tissue remodelling [67].     
    
Conclusion 
Achilles tendon injuries, whether partial or complete, are common and carry significant morbidity and financial 
implications for the patient and health service. With current modalities the repair tissue rarely demonstrates the 
biomechanical and functional properties of native tendon. The role of tissue engineering in tendon repair or 
augmentation of repair has been investigated in animal models. The ideal source of MSCs still has not been 
agreed upon, and little is known regarding the signalling pathways involved in tenogenesis of MSCs. Whilst 
current studies have shown encouraging results with regards to improved biomechanical and histological 
properties, further work is required to ascertain the growth factors, biomaterials and source of stem cells 
required for tendon regeneration. 
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